GlassScriptPhysician profile
Vivek Garlapati
NPI 1114162211
$2,299.52
in general payments reported to CMS, 2019-2025
24 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $101 · 2021: $249 · 2022: $325 · 2023: $314 · 2024: $549 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368 · Education: $43.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.41 |
| Education | $43.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.27 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $213.55 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $180.60 | 2020-2024 | Livdelzi |
| Celltrion USA INC. | $136.99 | 2024-2025 | Vegzelma, Zymfentra |
| Takeda Pharmaceuticals U.S.A., INC. | $131.33 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $105.77 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $104.37 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $86.95 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $74.73 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $73.45 | 2022-2023 | Dupixent |
| Madrigal Pharmaceuticals | $67.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $48.99 | 2024 | Omvoh |
| Allergan, INC. | $37.21 | 2019 | |
| Novo Nordisk INC | $36.82 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $32.09 | 2021-2023 | Suflave |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.47 | 2025 | |
| Pfizer INC. | $21.28 | 2025 | |
| Aimmune Therapeutics, INC. | $20.49 | 2024 | |
| Redhill Biopharma INC. | $20.20 | 2023 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.14 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $18.06 | 2020 | |
| Merck Sharp & Dohme LLC | $17.75 | 2023 | Dificid |
| Capsovision, INC. | $14.30 | 2024 | Capsocam Plus |
| Endogastric Solutions, INC | $7.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Garlapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.